Showing 5481-5490 of 5621 results for "".
- CDC Launches the Nation’s First Vision and Eye Health Surveillance Systemhttps://modernod.com/news/cdc-launches-the-nations-first-vision-and-eye-health-surveillance-system/2479924/The Centers for Disease Control and Prevention (CDC) has developed the nation’s first Vision and Eye Health Surveillance System (VEHSS). Launched in collaboration with the National Opinion Research Center (NORC), the VEHSS is designed to help health care professionals, researchers, policymakers,
- Penn’s Experimental Gene Therapy Saves Night Vision in Dogs, Paving the Way for Human Testshttps://modernod.com/news/penns-experimental-gene-therapy-saves-night-vision-in-dogs-paving-the-way-for-human-tests/2479925/In 1990, scientists discovered a genetic mutation that turns an important light-sensing protein in the retina into a toxin that steadily destroys the ability to see in low light. <
- EyeGate Announces Enrollment of First Patient in PRK Pilot Studyhttps://modernod.com/news/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study/2479928/EyeGate Pharmaceuticals announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) surgery.
- University of Toledo Chemists Discover How Blue Light Speeds Blindnesshttps://modernod.com/news/university-of-toledo-chemists-discover-how-blue-light-speeds-blindness/2479929/Blue light from digital devices and the sun transforms vital molecules in the retina into cell killers, according to optical chemistry research at The University of Toledo. The process outlined in the study, which was recently published in the journal
- Mount Sinai Researchers Discover How to Restore Vision Using Retinal Stem Cellshttps://modernod.com/news/mount-sinai-researchers-discover-how-to-restore-vision-using-retinal-stem-cells/2479939/Researchers at Mount Sinai have successfully restored vision in mice through activating retinal stem cells, something that has never been done before. Their study, published in the August 15 online issue of Nature, could transform treatment for patients with retinal degenerative diseases
- UnitedHealthcare Eye Care Program Aims to Give Children Access to Comprehensive Eye Exams and Glasseshttps://modernod.com/news/unitedhealthcare-eye-care-program-aims-to-give-children-access-to-comprehensive-eye-exams-and-glasses/2479940/UnitedHealthcare has launched a new program that aims to improve access to comprehensive eye exams and prescription glasses for children across the country, helping address the unique eye-health challenges young people face. The UnitedHealthcare Children’s Eye Care Program will help expand
- Glasses May Boost Productivity for Rural Workershttps://modernod.com/news/glasses-may-boost-productivity-for-rural-workers/2479941/Providing reading glasses may be an inexpensive way to improve productivity, as well as earnings and quality of life, among workers in developing countries, suggests a clinical trial involving tea pickers in India, according to a Reuters Health
- Aerie Pharmaceuticals Reports Topline Results From Rhopressa Mechanism of Action Studyhttps://modernod.com/news/aerie-pharmaceuticals-reports-topline-result-from-rhopressa-mechanism-of-action-study/2479942/Aerie Pharmaceuticals announced topline efficacy results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of Rhopressa (netarsudil ophthalmic solution 0.02%) on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. While seve
- Astellas Announces Acquisition of Quethera, Maker of Gene Therapy Program for Glaucomahttps://modernod.com/news/astellas-announces-acquisition-of-quethera-maker-of-gene-therapy-program-for-glaucoma/2479949/Astellas Pharma has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma. Under the terms of the agreement, Astellas may pay up to £85 million ($1
- Ivantis Receives FDA Approval for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS)https://modernod.com/news/ivantis-receives-fda-approval-for-the-hydrus-microstent-device-for-minimally-invasive-glaucoma-surgery-migs/2479950/Ivantis announced that it has received FDA approval for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. “The Hydrus represents a unique next-generation